We know that Steve and Prof Miles Prince (and the rest of the...

We know that Steve and Prof Miles Prince (and the rest of the biotech experts here in Aust) have been in discussions with Govt about the need for more investment, policy-making and infrastructure for a long time. It came to the fore when the media got on board last year to highlight the inadequacies - its been given national exposure. Aust regulators have been under pressure to help finance and advance operations like Aurora Biosynthetics. And, this hsn't happened overnight.

Paul Hopper (love or hate him) is behind the grand plan to build our own immunotherapy manufacturing ecosystem in Aust. Pick the brains of the global experts, license worthy technologies and advance them here so that Aussies can access the therapies instead of the govt randomly choosing to pay to send Aussies overseas for life-saving treatments. Aurora Biosynthetics is a subsidiary of Myeloid Therapeutics which is based in the US. Aust needs to become a manufacturer and to become self-reliant. PH has high aspirations!

I reckon Gavin Shepherd may have got first-hand knowledge of the potential of OmniCAR to the point of wanting to get on the board to see it advanced further. Whether he will nominate as a candidate is possible. Steven seems impressed with our Director of Clinical Affairs & Operations - Upaly:-

• Over 17 years of experience in clinical development, driving programs from pre-clinical development through to regulatory submissions and successful commercialisation
• Experience in leading global studies in oncology, including immuno-oncology
• Formerly Beigene Global Clinical Program Lead
• CRO experience with Chiltern International; Quintiles Research
• Background in Pharmacy and Pharmaceutical Marketing

To me, she seems like the lead candidate with these credentials and where PTX-100 is now positioned. With marketing bordering on non-existent for what seems like an eternity, its time that SH were ingratiated with the new board members and management team. It has transitioned from what was more akin to a startup research-based pre-clinical biotech co. to one that is geared towards development and potential commercialisation.